Cognitive medicine and biomarkers

Cognition is a term for the human ability to learn, think and process information in our brains. Our cognitive functions must work for us to be able to lead a normal everyday life.

We conduct collaborative randomised controlled clinical trials across a broad spectrum of fields – ranging from neurogeriatric, psychiatric and biomarker research – both nationally and internationally.

By using digital neuropsychological assessment tools (Mindmore IPAD and GERAS); biochemical analysis of cerebrospinal fluid and blood; microbiota sampling; brain imaging (magnetic resonance imaging, MRI ); and rating of psychological, psychiatric and cognitive symptoms, we work to bridge the knowledge gap that exists for a number of cognitive disorders.

Ongoing research is focused on the following topics:
• Cognitive Medicine including psychiatric, neurological and, cognitive symtomatology and  biomarker analyses in the blood and cerebrospinal fluid
• Behavioural and psychiatric symptoms in dementia ( BPSD) and biomarkers
• Old Age Psychiatry and cognitive therapy
• Physical cctivity and nutrition as treatment for depression/anxiety (RCT)
• Covid 19 long-term effects in the geriatric population and in collaboration with the  primary care (RCT)
Alzheimer's disease

Collaboration
Victor Bloniecki Kallio victor.bloniecki.kallio@ki.se 
Professor Jonas Bergquist Uppsala University
Sophie Erhardt Professor KI
Per Thunberg, Örebro University
Scott Montgomery, Örebro University
Jonas Persson, Örebro University